News & Updates

A novel artificial intelligence (AI) classifier can detect hepatocellular carcinoma (HCC) signatures in routine blood tests up to 1 year before clinical diagnosis, as shown in a study from Hong Kong.

Patients with gastrointestinal large cell neuroendocrine carcinoma (GILCNEC) show varying prognosis depending on the site of the primary tumour, suggests a study. Unfortunately, there remains no standardized consensus guidelines to manage GILCNEC.

Treatment with the combination of regorafenib, nivolumab, and short-course radiotherapy (SCRT) in the neoadjuvant setting has induced response in stage II-III rectal adenocarcinoma in the phase II REGINA trial, meeting the predefined statistical criteria.